Bairitone health SOMNAR
Bairitone Health is developing a regulated, noninvasive diagnostic platform for obstructive sleep apnea that helps clinicians identify the anatomical source of airway collapse and guide therapy selection. For partners across sleep medicine, medtech, and care delivery, Bairitone addresses a critical gap between diagnosis and treatment: current sleep tests measure severity, but they do not predict which therapy will work for which patient. The main alternative, Drug Induced Sleep Endoscopy, can provide that insight but requires sedation in the operating room and is costly, invasive, and inefficient.
Bairitone is designed to move this predictive diagnostic capability into the home through noninvasive acoustic sensing and proprietary signal processing. Our platform is intended to generate clinically actionable insights that can support more precise use of therapies such as CPAP, oral appliances, surgery, and nerve stimulation, while improving workflow efficiency and patient access.
The company has developed and internally validated its core technology and is advancing through design controls, clinical planning, and regulatory execution. Bairitone has received FDA Breakthrough Device designation, NIH SBIR support, and recognition from the American Academy of Sleep Medicine as a Sleep Medicine Disruptor. We were also selected in the top 10% of MedTech Innovator applicants out of more than 1,800 companies.
Our next phase is focused on pivotal studies, FDA De Novo authorization, and commercialization readiness. We see strong opportunity to partner with clinical leaders, strategic industry players, and innovation-focused organizations seeking to advance precision sleep medicine.
About Bairitone Health
Bairitone Health is a health technology company based in Houston, Texas, that develops AI-driven solutions for the diagnosis and management of obstructive sleep apnea (OSA). Its primary technology, Somnar, is a non-invasive, skin-mounted sleep sonar sensor patch that captures natural vibrations during sleep. By using artificial intelligence to analyze these vibrations, the platform maps airway anatomy and function throughout the night, enabling clinicians to identify the specific locations and root causes of airway obstruction without the need for traditional, invasive procedures like MRI, X-ray, or ultrasound.
The platform aims to solve the problem of trial-and-error in sleep apnea care by moving anatomic assessment from the clinic to the home. By providing a detailed, dynamic map of the airway, Somnar helps providers choose the most effective, personalized therapies for patients, ranging from surgical interventions to dental appliances and other devices. The company’s technology has received FDA Breakthrough Device Designation and is currently in the research and development phase, supported by NIH SBIR funding for its goal of streamlining OSA diagnostic processes and improving clinical outcomes.
delivered to your inbox.